title: [Immunological monitoring of endogenous attack-like psychoses].
abstract: To analyze the possibility of using immunological parameters for the assessment of the activity of the process and prediction of the quality and completion of remission, we compared the dynamics of clinical and immunological parameters in 76 patients with endogenous attack-like psychoses during pharmacotherapy of a psychotic episode. Authors confirmed evidence for the activation of innate and adaptive immunity in the acute stage of psychosis as well as the correlation between immunological parameters (leukocyte elastase (LE) activity, alpha(1)-proteinase inhibitor (alpha(1)-PI), the level of autoantibodies to nerve growth factor (Aab-NGF)) and clinical symptoms assessed with the PANSS. The improvement of the clinical state assessed by the reduction in PANSS total score was noted in all patients though there were variations in the dynamics of immunological parameters. The increase of immunological parameters, along with the absence of changes at the discharge from the hospital, suggests that the remission was of low quality and the pathological process did not attenuate. Outpatient examination revealed the different dynamics of psychopathological disorders: stable state in 50% patients, moderate worsening of psychological state in 50% patients. Worsening of clinical symptoms after the discharge and in the outpatient stage was correlated with the elevation of the activity/level of immunological parameters. The changes in LE activity and Aab-NGF level precede the changes in mental state of patients in the following 1-2 months. These parameters may be used for monitoring of patients and prediction of quality and completion of remission.
authors.forename: T P
authors.initials: TP
authors.lastname: Kliushnik
authors.forename: S A
authors.initials: SA
authors.lastname: Zozulia
authors.forename: L V
authors.initials: LV
authors.lastname: Androsova
authors.forename: Z V
authors.initials: ZV
authors.lastname: Sarmanova
authors.forename: I N
authors.initials: IN
authors.lastname: Otman
authors.forename: A M
authors.initials: AM
authors.lastname: Dupin
authors.forename: G P
authors.initials: GP
authors.lastname: Panteleeva
authors.forename: I V
authors.initials: IV
authors.lastname: Oleĭchik
authors.forename: L I
authors.initials: LI
authors.lastname: Abramova
authors.forename: S A
authors.initials: SA
authors.lastname: Stoliarov
authors.forename: E S
authors.initials: ES
authors.lastname: Shipilova
authors.forename: O A
authors.initials: OA
authors.lastname: Borisova
mesh_terms: D056704:Adaptive Immunity; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D019272:Leukocyte Elastase / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015166:Monitoring, Immunologic; D020932:Nerve Growth Factor / Q000276:immunology; D011379:Prognosis; D011618:Psychotic Disorders / Q000175:diagnosis* / Q000276:immunology*; D055815:Young Adult; D000515:alpha 1-Antitrypsin / Q000276:immunology
chemical_list: D000515:alpha 1-Antitrypsin; D020932:Nerve Growth Factor; D019272:Leukocyte Elastase